Results 21 to 30 of about 43,675 (258)
Epigenetics, 2019 EZH2 is overexpressed in poor-prognostic chronic lymphocytic leukaemia (CLL) cases, acting as an oncogene; however, thus far, the EZH2 target genes in CLL have not been disclosed.
Subazini Thankaswamy Kosalai +8 more
doaj +1 more source
Cancer Biology & Medicine, 2020 Objective: Pancreatic ductal adenocarcinoma (PDAC) is a disease with high mortality. Many so-called “junk” noncoding RNAs need to be discovered in PDAC.
Ting Han +7 more
doaj +1 more source
Journal of Inflammation Research, 2022 Yingze Li,* Guojian Fang,* Wei Cao,* Jiali Yuan,* Shuai Song, Hong Peng, Yuepeng Wang, Qunshan Wang Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, People’s ...
Li Y +7 more
doaj
Epigenetics, 2021 A stressor can induce resilience in another, different stressor, a phenomenon known as cross-tolerance. To learn if cross-tolerance is governed by epigenetic regulation, we used embryonic heat conditioning (EHC) in chicks, during the development of the ...
Tali Rosenberg +4 more
doaj +1 more source
The Tumorigenic Properties of EZH2 are Mediated by MiR-26a in Uveal Melanoma
Frontiers in Molecular Biosciences, 2021 Background: The polycomb group protein enhancer of zeste homolog 2 (EZH2) has been found to be highly expressed in various tumors, and microRNA-26a (miR-26a) is often unmodulated in cancers. However, the functions of these two molecules in uveal melanoma
Yao Li +3 more
doaj +1 more source
Molecular switch of EZH2 in hypoxia [PDF]
Cell Cycle, 2016 Over the past decades, several reports on a non-canonical function of Ezh2 and discoveries of its novel partners, other than its canonical PRC2 members i.e.
Sylvia, Mahara, Wee Joo, Chng, Qiang, Yu
openaire +2 more sources
HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2 [PDF]
Open Biology, 2019 Increasing evidence suggests that dysregulation of long non-coding RNAs (lncRNAs) is implicated in chemoresistance in cancers. However, the function and molecular mechanisms of lncRNAs in gastric cancer chemoresistance are still not well understood.
Yafei Ye +6 more
doaj +1 more source
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer
Cell Reports, 2018 Summary: Although EZH2 enzymatic inhibitors have shown antitumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here
Peijing Zhang +35 more
doaj +1 more source
EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma
Clinical Epigenetics, 2023 Background Overexpressed EZH2 is oncogenically involved in the pathogenesis of different cancerous contexts including extranodal natural killer/T cell lymphoma (ENKTL). However, the underlying mechanisms of EZH2 upregulation have not been fully clarified
Boheng Li +10 more
doaj +1 more source
Evaluation of EZH2 and ERRα in colorectal carcinoma: an immunohistochemical study
Polish Journal of Pathology, 2022 The combined immunohistochemical evaluation of EZH2 (enhancer of zeste homolog 2) and ERRα (estrogen-related receptor α), in relation to clinicopathological prognostic factors and patients’ outcome, has not been performed yet in colorectal carcinoma (CRC)
Hoda Abou Gabal +4 more
doaj +1 more source